Royalty Pharma (RPRX) PT Raised to $67 at Morgan Stanley

October 7, 2026 7:59 AM

Morgan Stanley analyst Terence Flynn raised the price target on Royalty Pharma (NASDAQ: RPRX) to $67.00 (from $65.00) while maintaining a Overweight rating.

No results found